Azaindole derivatives as inhibitors of p38 kinase

Details Azaindole derivatives as inhibitors of p38 kinase Azaindole derivatives as inhibitors of p38 kinase

2008-07-01

2008-07-01

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S362000

Reexamination Certificate

active

10683656

ABSTRACT:
The invention is directed to methods to inhibit p38 kinase, preferably p38-α using compounds which are azaindoles wherein the azaindoles are coupled through a piperidine or piperazine type linker to another cyclic moiety.

REFERENCES:
patent: 6476045 (2002-11-01), Dinnell et al.
patent: 6649636 (2003-11-01), Ando et al.
patent: 6897207 (2005-05-01), Cox et al.
patent: 2002/0183319 (2002-12-01), Liang et al.
patent: 2005/0209269 (2005-09-01), Salom et al.
patent: 2005/0256151 (2005-11-01), Salom et al.
patent: 2006/0046977 (2006-03-01), Nunes et al.
patent: WO 96/40143 (1996-12-01), None
patent: WO 97/26252 (1997-07-01), None
patent: WO 98/06715 (1998-02-01), None
patent: WO 98/07425 (1998-02-01), None
patent: WO 99/61426 (1999-12-01), None
patent: WO 00/12074 (2000-03-01), None
patent: WO 00/59904 (2000-10-01), None
patent: WO 00/71535 (2000-11-01), None
patent: WO 2004/032874 (2004-04-01), None
Janssens et al. “Bicyclic heterocycliyl . . . ” Ca 104:68856 (1986).
Houpis et al. “Synthesis of functionalized . . . ” CA 122:105718 (1995).
Furuya et al. “Preparation of thieno . . . ” Ca 124:202226 (1995).
Buzzetti et al. “Preparation and formulation . . . ” CA 124:260834 (1996).
Kim et al. “Piperazinecarboxamide . . . ” CA 125:58548 (1996).
Suzuki et al. “preparation of condensed . . . ” Ca 127:135807 (1997).
Ewing et al. “Substituted piperazinone . . . ” CA 131:130007 (1999).
Salom et al. “Preparation of pyrrolo[2,3-b]pyridine . . . ” CA 143:133351 (2005).
Salom et al. “Preparation of . . . ” CA 143:347150 (2005).
Ledeboer et al. “Pyrrolopyridines . . . ” CA 146:27814 (2006).
Saavedra et al. “preparation of thienopyridine . . . ” CAS AN 2007:17769 (2007).
Bundgaard “design of prodrugs” p. 1, 27-28 (1986).
King “Bioisosters . . . ” Med. chem. principle and Practice p. 206-208 (1994).
Patani et al. “Bioisosterism . . . ” Chem Rev. v90 p. 3147, 3168 (1990).
International Search Report mailed on Apr. 13, 2004 for PCT patent application No. PCT/US03/32171 filed on Oct. 9, 2003, 4 pages.
U.S. Appl. No. 60/395,693, filed Jul. 11, 2002.
Colvin et al., Tetrahedron Lett. (1982) 23(37):3835-3836.
Jiang et al., J. Biol. Chem. (1996) 271:17920-17926.
Kumar et al., Biochem. Biophys. Res. Comm. (1997) 235:533-538.
Li et al., Biochem. Biophys. Res. Comm. (1996) 228:334-340.
Rewcastle et al., J. Med. Chem. (1996) 39:1823-1835.
Stein et al., J. Biol. Chem. (1997) 272:19509-19517.
Wang et al., J. Biol. Chem. (1997) 272:23668-23674.
Ngo et al., In the Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al., (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495, Ref-U, Form-892.
Mavunkel et al., Bioorganic and Medicinal Chemistry Letters, 2003, vol. 13, pp. 3087-3090.
International Search Report Mailed on Aug. 18, 2005 for PCT/US2005/12969 filed on Apr. 15, 2005.

Affiliated with

Also associated with

Rating

Azaindole derivatives as inhibitors of p38 kinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Azaindole derivatives as inhibitors of p38 kinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindole derivatives as inhibitors of p38 kinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3929905